Background The second generation drug-eluting stents have been shown to improve angiographic and clinical outcomes after percutaneous myocardial revascularisation, but its performance in small coronary arteries has not been investigated.
Objectives To evaluate the safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Resolute zotarolimus-eluting stent (ZES) in small vessels.
Methods In this study, we studied a cohort of 412 patients with small coronary vessels (reference diameter <2.75 mm). EES (54.1% of pts) and ZES (45.9% of pts) were used in our study.
Results Mean angiographic in-stent and in-segment late loss was non-significantly less in the EES group compared with the ZES group, (0.16±0.51 vs 0.18±0.44 mm; p=0.209 for in-stent; 0.12±0.36 mm vs 0.13±0.28 mm; p=0.387 for in-segment). EES resulted in a non-significant reduction in composite major adverse cardiac events at 1 year (6.4% vs 8.2%; p=0.130). At 1 year, the rate of non-Q-wave myocardial infarction was also the same in both groups (p=0.055).
Conclusions In patients with small vessel coronary arteries, the XIENCE V EES was not superior to the Resolute ZES.